Cargando…
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485066/ https://www.ncbi.nlm.nih.gov/pubmed/28273356 http://dx.doi.org/10.1002/jcph.876 |